QF
CASC

QVT Financial’s Cascadian Therapeutics, Inc. CASC Stock Holding History

QVT Financial’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-800,000
Closed -$3.31M – 85
2017
Q1 		$3.31M Buy
+800,000
New +$3.36M 0.1% 67
2015
Q4 		– Sell
-102,395
Closed -$1.68M – 90
2015
Q3 		$1.68M Buy
102,395
+24,604
+32% +$504K 0.06% 83
2015
Q2 		$1.75M Sell
77,791
-642,503
-89% -$10.2M 0.03% 81
2015
Q1 		$7.04M Sell
720,294
-120,453
-14% -$1.18M 0.39% 58
2014
Q4 		$9.48M Sell
840,747
-276,931
-25% -$3.01M 0.47% 52
2014
Q3 		$12.9M Buy
1,117,678
+179,528
+19% +$2.74M 0.66% 45
2014
Q2 		$18.2M Hold
938,150
– – 0.99% 40
2014
Q1 		$16.8M Sell
938,150
-12,233
-1% -$201K 0.96% 37
2013
Q4 		$10M Buy
950,383
+306,700
+48% +$3.43M 0.59% 52
2013
Q3 		$7.96M Buy
+643,683
New +$6.78M 0.54% 46

Other funds holding CASC

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

QVT Financial's CASC Position: Q2 2017 in Review

QVT Financial sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2017, closing a stake of 800,000 shares — an estimated $3.31M sold.

QVT Financial first reported a position in CASC in Q3 2013 and held it in 10 quarters. The position peaked at $18.2M in Q2 2014. 76 funds tracked by Wall St. Rank hold CASC as of Q2 2017.

  • QVT Financial reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • QVT Financial sold 800,000 Cascadian Therapeutics, Inc. shares in Q2 2017, an estimated $3.31M.
  • QVT Financial first reported a position in Cascadian Therapeutics, Inc. in Q3 2013 and held it in 10 quarters.
  • QVT Financial's Cascadian Therapeutics, Inc. position peaked at $18.2M in Q2 2014.
  • 76 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2017.

Based on QVT Financial's 13F filing for Q2 2017, filed 14 Aug 2017.